Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQ001S vs Budesonide Suspension in Mild Asthma
NCT04933383Phase 2Completed
- Sponsor
- Aquilon Pharma
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Injectable Hydrogels, Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AQ001S in asthma (2 arms), sponsored by Aquilon Pharma. Primary endpoints: Change From Baseline in PC20 (Provocative Concentration of Methacholine causing 20% FEV1 drop) at Day 58 and Incidence of Treatment-Emergent Adverse Events at Day 58. Started Jul 2021; status: completed.
02
Drugs
AQ001S
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04933383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933383.